- 著者
-
Kazutaka UCHIDA
Nobuyuki SAKAI
Hiroshi YAMAGAMI
Kohei UEMURA
Hirotoshi IMAMURA
Masataka TAKEUCHI
Manabu SHIRAKAWA
Fumihiro SAKAKIBARA
Koichi HARAGUCHI
Naoto KIMURA
Kentaro SUZUKI
Junichi AYABE
Daisuke YAMAMOTO
Seigo SHINDO
Atsushi KIMOTO
Kenichi MORITA
Yoshinori AKIYAMA
Hidesato TAKEZAWA
Shingo TOYOTA
Kanta TANAKA
Shigen KASAKURA
Eisuke TSUKAGOSHI
Toshihiro UEDA
Shinichi YOSHIMURA
Japan Trevo Registry Investigators
- 出版者
- The Japan Neurosurgical Society
- 雑誌
- Neurologia medico-chirurgica (ISSN:04708105)
- 巻号頁・発行日
- pp.2023-0069, (Released:2023-10-18)
- 参考文献数
- 18
- 被引用文献数
-
2
Endovascular therapy (EVT) for real-world patients after extended time frames is associated with concerns about its efficacy and safety. We conducted a prospective registry at 77 centers between November 2019 and October 2020. The registry criteria included patients treated with Trevo Retriever alone or in combined therapy with an aspiration catheter. The primary outcome was effective reperfusion (thrombolysis in cerebral infarction grade ≥ 2b), the secondary outcome was a modified Rankin scale 0-2 at 90 days, and the safety outcomes were worsening of neurologic symptoms within 24 h postoperatively, intracranial hemorrhage (ICH) within 24 h after EVT and mortality. We also exlpored the difference between patients whose last known well time (LKWT) to a puncture was less than 6 h (0-6 h) and those whose LKWT was 6 h or more but less than 24 h (6-24 h). Among the 1041 patients registered, 1025 patients were analyzed. The mean age was 76.9 years, and 53.6% of the participants were males. The 6-24 h group was 206/998 (20.6%), the median National Institute of Health Stroke Scale (NIHSS) score at admission was 18, and the median Alberta Stroke Program Early CT score was 8. Combined technique as the first pass was used on 817 (79.7%) patients. The primary outcome was 934 (91.1%). The secondary outcome was 433/1021 (42.4%). Symptomatic ICH, any ICH, and mortality were 10/1019 (1.0%), 311/1019 (30.5%), and 75 (7.3%). In the subanalysis, the 6-24 h group was lower in NIHSS (median;18 vs 16), and the secondary outcome was not significantly different in the <6 h group. Even after treatment time expansion, this result was comparable to other Trevo-based trials and nationwide registries.